請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52216
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林俊宏 | |
dc.contributor.author | Chih-Chia Chang | en |
dc.contributor.author | 張志嘉 | zh_TW |
dc.date.accessioned | 2021-06-15T16:09:41Z | - |
dc.date.available | 2018-08-31 | |
dc.date.copyright | 2015-08-31 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-18 | |
dc.identifier.citation | 1 Giusti, C. Association of Helicobacter pylori with central serous chorioretinopathy hypotheses regarding pathogenesis. Med Hypotheses 63, 524-527 (2004).
2 Blaser, M. J. Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep 7, 956-960 (2006). 3 Yamaoka, Y., Kato, M. & Asaka, M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 47, 1077-1083 (2008). 4 Vannarath, S. et al. Virulence genes of Helicobacter pylori in gastritis, peptic ulcer and gastric cancer in Laos. Asian Pac J Cancer Prev 15, 9027-9031 (2014). 5 Schneider, N. et al. Role of Helicobacter pylori CagA Molecular Variations in Induction of Host Phenotypes with Carcinogenic Potential. J Infect Dis 199, 1218-1221 (2009). 6 Brown, L. M. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22, 283-297 (2000). 7 Correa, P. & Piazuelo, M. B. Natural history of Helicobacter pylori infection. Digest and Liver Dis 40, 490-496 (2008). 8 Jang, E. J. et al. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. J Gastroenterology Hepatol 23, S278-S285 (2008). 9 Tan, H. J. & Goh, K. L. Changing epidemiology of Helicobacter pylori in Asia. Journal of Digestive Diseases 9, 186-189 (2008). 10 Hatakeyama, M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 4, 688-694 (2004). 11 Bauer, B. et al. The Helicobacter pylori virulence effector CagA abrogates human beta-defensin 3 expression via inactivation of EGFR signaling. Cell Host Microbe 11, 576-586 (2012). 12 Botham, C. M., Wandler, A. M. & Guillemin, K. A transgenic Drosophila model demonstrates that the Helicobacter pylori CagA protein functions as a eukaryotic Gab adaptor. PLoS Pathog 4, e1000064 (2008). 13 Buti, L. et al. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci U S A 108, 9238-9243 (2011). 14 Chan, R. J. & Feng, G. S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109, 862-867 (2007). 15 Ferreira, R. M., Machado, J. C., Cameiro, F. & Figueiredo, C. The Number of Helicobacter pylori cagA EPIYA C Tyrosine Phosphorylation Motifs Is Associated with Histopathological Features of Chronic Gastritis. Gastroenterology 136, A549-A549 (2009). 16 Hatakeyama, M. Anthropological and clinical implications for the structural diversity of the Helicobacter pylori CagA oncoprotein. Cancer Sci 102, 36-43 (2011). 17 Hayashi, T. et al. Tertiary structure-function analysis reveals the pathogenic signaling potentiation mechanism of Helicobacter pylori oncogenic effector CagA. Cell Host Microbe 12, 20-33 (2012). 18 Hayashi, T., Morohashi, H. & Hatakeyama, M. Bacterial EPIYA effectors--where do they come from? What are they? Where are they going? Cell Microbiol 15, 377-385 (2013). 19 Higashi, H. et al. EPIYA motif is a membrane-targeting signal of Helicobacter pylori virulence factor CagA in mammalian cells. J Biol Chem 280, 23130-23137 (2005). 20 Huang, F. Y. et al. Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1beta activation of nitric oxide production in gastric cancer cells. Cancer 118, 4969-4980 (2012). 21 Lee, I. O. et al. Helicobacter pylori CagA phosphorylation status determines the gp130-activated SHP2/ERK and JAK/STAT signal transduction pathways in gastric epithelial cells. J Biol Chem 285, 16042-16050 (2010). 22 Matozaki, T., Murata, Y., Saito, Y., Okazawa, H. & Ohnishi, H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci 100, 1786-1793 (2009). 23 Mueller, D. et al. c-Src and c-Abl kinases control hierarchic phosphorylation and function of the CagA effector protein in Western and East Asian Helicobacter pylori strains. J Clin Invest 122, 1553-1566 (2012). 24 Murata-Kamiya, N., Kikuchi, K., Hayashi, T., Higashi, H. & Hatakeyama, M. Helicobacter pylori exploits host membrane phosphatidylserine for delivery, localization, and pathophysiological action of the CagA oncoprotein. Cell Host Microbe 7, 399-411 (2010). 25 Backert, S. & Selbach, M. Role of type IV secretion in Helicobacter pylori pathogenesis. Cell Microbiol 10, 1573-1581 (2008). 26 Haque, M., Hirai, Y., Yokota, K. & Oguma, K. Steryl glycosides: a characteristic feature of the Helicobacter spp.? J Bacteriol 177, 5334-5337 (1995). 27 Wunder, C. et al. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat Med 12, 1030-1038 (2006). 28 Wang, H. J., Cheng, W. C., Cheng, H. H., Lai, C. H. & Wang, W. C. Helicobacter pylori cholesteryl glucosides interfere with host membrane phase and affect type IV secretion system function during infection in AGS cells. Mol Microbiol 83, 67-84 (2012). 29 Ekstrom, A. M., Held, M., Hansson, L. E., Engstrand, L. & Nyren, O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 121, 784-791 (2001). 30 Lee, S. J., Lee, B. I. & Suh, S. W. Crystal structure of the catalytic domain of cholesterol-alpha-glucosyltransferase from Helicobacter pylori. Proteins 79, 2321-2326 (2011). 31 Tannaes, T., Bukholm, G., Dekker, N. & Appelmelk, B. J. Molecular mechanism of phase variation in a virulence gene of H-pylori. Gut 45, A24-A24 (1999). 32 DeSilva, N. S. & Quinn, P. A. Characterization of phospholipase A(1), A(2), C activity in Ureaplasma urealyticum membranes. Mol Cell Biochem 201, 159-167 (1999). 33 Hesse, M. et al. Sequence and expression of the chicken membrane-associated phospholipases A1 alpha (LIPH) and beta (LIPI). Mol Biol Rep 39, 761-769 (2012). 34 Scandella, C. J. & Kornberg, A. A membrane-bound phospholipase A1 purified from Escherichia coli. Biochemistry 10, 4447-4456 (1971). 35 Dennis, E. A. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 269, 13057-13060 (1994). 36 Liscovitch, M., Czarny, M., Fiucci, G. & Tang, X. Phospholipase D: molecular and cell biology of a novel gene family. Biochem J 345 Pt 3, 401-415 (2000). 37 Tannaes, T., Dekker, N., Bukholm, G., Bijlsma, J. J. & Appelmelk, B. J. Phase variation in the Helicobacter pylori phospholipase A gene and its role in acid adaptation. Infect Immun 69, 7334-7340 (2001). 38 Tannaes, T. & Bukholm, G. Cholesteryl-6-O-acyl-alpha-D-glucopyranoside of Helicobacter pylori relate to relative lysophospholipid content. FEMS Microbiol Lett 244, 117-120 (2005). 39 Istivan, T. S. & Coloe, P. J. Phospholipase A in Gram-negative bacteria and its role in pathogenesis. Microbiology 152, 1263-1274 (2006). 40 Snijder, H. J. et al. Structural evidence for dimerization-regulated activation of an integral membrane phospholipase. Nature 401, 717-721 (1999). 41 Grant, K. A., Belandia, I. U., Dekker, N., Richardson, P. T. & Park, S. F. Molecular characterization of pldA, the structural gene for a phospholipase A from Campylobacter coli, and its contribution to cell-associated hemolysis. Infect Immun 65, 1172-1180 (1997). 42 Leid, M. Hot Papers - Molecular-Biology - Purification, Cloning and Rxr Identity of the Hela-Cell Factor with Which Rar or Tr Heterodimerizes to Bind Target Sequences Efficiently by Leid,M., Kastner,P., Lyons,R., Et-Al. Scientist 7, 17-17 (1993). 43 McFarland, D. C. Preparation of pure cell cultures by cloning. Methods Cell Sci 22, 63-66 (2000). 44 Kingma, R. L. et al. Unusual catalytic triad of Escherichia coli outer membrane phospholipase A. Biochemistry 39, 10017-10022 (2000). 45 Newby, Z. E. et al. A general protocol for the crystallization of membrane proteins for X-ray structural investigation. Nat Protoc 4, 619-637 (2009). 46 Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254 (1976). 47 Switzer, R. C., 3rd, Merril, C. R. & Shifrin, S. A highly sensitive silver stain for detecting proteins and peptides in polyacrylamide gels. Anal Biochem 98, 231-237 (1979). 48 Salmond, G. P. C. & Whittenbury, R. Biology of Microorganisms, 4th Edition - Brock,Td, Smith,Dw, Madigan,Mt. Nature 314, 49-49 (1985). 49 Kolb, H. C., Finn, M. G. & Sharpless, K. B. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl 40, 2004-2021 (2001). 50 van der Vusse, G. J., Roemen, T. H. & Reneman, R. S. The content of non-esterified fatty acids in rat myocardial tissue. A comparison between the Dole and Folch extraction procedures. J Mol Cell Cardiol 17, 527-531 (1985). 51 Sattler, W., Puhl, H., Hayn, M., Kostner, G. M. & Esterbauer, H. Determination of fatty acids in the main lipoprotein classes by capillary gas chromatography: BF3/methanol transesterification of lyophilized samples instead of Folch extraction gives higher yields. Anal Biochem 198, 184-190 (1991). 52 Gerber, F. et al. Practical aspects of fast reversed-phase high-performance liquid chromatography using 3 microm particle packed columns and monolithic columns in pharmaceutical development and production working under current good manufacturing practice. J Chromatogr A 1036, 127-133 (2004). 53 Xiang, Y., Liu, Y. & Lee, M. L. Ultrahigh pressure liquid chromatography using elevated temperature. J Chromatogr A 1104, 198-202 (2006). 54 Horvath, C. G., Preiss, B. A. & Lipsky, S. R. Fast liquid chromatography: an investigation of operating parameters and the separation of nucleotides on pellicular ion exchangers. Anal Chem 39, 1422-1428 (1967). 55 Wysocki, V. H., Resing, K. A., Zhang, Q. & Cheng, G. Mass spectrometry of peptides and proteins. Methods 35, 211-222 (2005). 56 Lee, M. S. & Kerns, E. H. LC/MS applications in drug development. Mass Spectrom Rev 18, 187-279 (1999). 57 Chen, W. W., Niepel, M. & Sorger, P. K. Classic and contemporary approaches to modeling biochemical reactions. Genes Dev 24, 1861-1875 (2010). 58 Stroppolo, M. E., Falconi, M., Caccuri, A. M. & Desideri, A. Superefficient enzymes. Cell Mol Life Sci 58, 1451-1460 (2001). 59 Yu, R. C. & Rappaport, S. M. A lung retention model based on Michaelis-Menten-like kinetics. Environ Health Perspect 105, 496-503 (1997). 60 Briggs, G. E. & Haldane, J. B. A Note on the Kinetics of Enzyme Action. Biochem J 19, 338-339 (1925). 61 Grima, R. & Schnell, S. A systematic investigation of the rate laws valid in intracellular environments. Biophys Chem 124, 1-10 (2006). 62 Hayakawa, K. et al. Determination of specific activities and kinetic constants of biotinidase and lipoamidase in LEW rat and Lactobacillus casei (Shirota). J Chromatogr B Analyt Technol Biomed Life Sci 844, 240-250 (2006). 63 Dekker, N., Tommassen, J., Lustig, A., Rosenbusch, J. P. & Verheij, H. M. Dimerization regulates the enzymatic activity of Escherichia coli outer membrane phospholipase A. J Biol Chem 272, 3179-3184 (1997). 64 Dovling Kaspersen, J. et al. Low-resolution structures of OmpADDM protein-detergent complexes. Chembiochem 15, 2113-2124 (2014). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52216 | - |
dc.description.abstract | 幽門螺旋桿菌主要生存在於人體胃部及十二指腸,主要會引起胃部的發炎、潰瘍、癌化,以及十二指腸的潰瘍等。當細菌附著於胃部上皮細胞時會利用第四型分泌系統將細胞毒素相關蛋白A ( Cytotoxin associated gene A, Cag A)送入宿主上皮細胞內,並被宿主細胞內的Src激酶在蛋白進行磷酸化作用,經過一系列下游之訊息傳遞作用促使細胞轉變成癌化細胞。
由於缺乏相關的生合成基因,當幽門螺旋桿菌會由環境中攝取膽固醇,並利用自身膽固醇-a-葡萄糖轉移酶 ( Cholesterol-α-glucosyltransferase )將膽固醇的第三位置羥基醣化轉變為膽固醇-α-D-口比喃葡糖苷 ( Cholesteryl-α-D-glucopyranoside,CG ),之後經過進一步修飾作用轉變為膽固醇-6-O-醯基-α-D-口比喃葡糖苷( Cholesteryl-6-O-acyl-α-D-glucopyranoside,CAG )、膽固醇-6-O-磷脂-α-D-口比喃葡糖苷 (Cholesteryl-6-O-phosphatidyl-α-D-glucopyranoside,CPG ),這些膽固醇糖苷類衍生物經過證實可使幽門螺旋桿菌避免被巨噬細胞吞噬,但是如何將CG乙醯化成為CAG的酵素並不清楚。 幽門螺旋桿菌hp0499基因在早期文獻中透過基因序列比對以及基因剔除實驗間接證實HP0499擁有磷酸脂酶A 1活性,該蛋白為一膜蛋白白可能鑲嵌在幽門螺旋桿菌外膜上。本論文中著重在測試不同的條件純化HP0499,最後利用界面活性劑純化出該蛋白,並利用帶螢光標定之CG受質,將此受質配合不同的磷酸脂類進行活性測試或催化反應,並利用LC/MS/MS及HPLC偵測產物生成,直接證實HP0499為擁有外膜磷酸脂酶A1及CAG合成酶之雙功能酵素。隨後進行一系列生化特性分析:包括酵素穩定度、溫度、pH、金屬離子、受質專一性,最終利用最佳條件進行酵素動力學探討,這些分析希望可以找出HP0499最適當的反應條件,也希望利用其反應條件產生擁有不同飽和程度及碳鏈長之CAG。 | zh_TW |
dc.description.abstract | Helicobacter pylori is a Gram-negative, microaerophilic bacterium present in the human stomach. H pylori infection has been largely associated to the development of duodenal ulcer and stomach cancer. Long-term H. pylori infection of the gastric mucosa might cause gastric cancer via severe inflammation, but no direct molecular link was demonstrated until Hatakeyama reported that the transfer of
H. pylori-derived Cytotoxin associated gene A (Cag A) to epithelial cells through a bacterial type IV secretion system promote an early event of gastric carcinogenesis. This pathogen hijacks cholesterol from the host and biosynthesis cholesteryl glucoside derivatives (CGds). In general, CGds are composed of cholesteryl α-D-glucopyranoside (CG), cholesteryl 6-O-phosphatidyl-α- D-glucopyranoside (CPG) and cholesteryl 6-O-acyl-α-D-glucopyranoside (CAG). Previous reports indicated that CGds were essential for impeding H. pylori phagocytosis and T cell activation. Our lab has recently discovered that CAG enhances the translocation of the CagA protein in to the host cell. The known enzyme cholesterol glucosyltrasferase catalyzes the formation of CG that is then converted to CAG by a possible enzyme, HP0499. In order to determine and characterize the function of HP0499, it is essential to prepare the recombinant HP0499 in E. coli. However, the major challenge was mainly attributed to poor purification. The successful expression and purification of HP0499 by detergent allowed us to obtain more pure recombinant protein with an improved yield. An HPLC and LC/MS/MS assay was established to use fluorophore-containing CG analogue, to study the enzyme function, activity, and substrate specificity. Finally, we identified that HP0499 has both phospholipaseA1 and CAG synthase activities. The standardized conditions can be further used to prepare CAG with different fatty acid chain lengths and various saturations. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T16:09:41Z (GMT). No. of bitstreams: 1 ntu-104-R02b46026-1.pdf: 3183919 bytes, checksum: a3d66d7328bafacfdb497ababb344385 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 目錄......................................................IV
圖表目錄 ..................................................VI 摘要....................................................VIII ABSTRACT...................................................X 第一章 緒論................................................1 1-1幽門螺旋桿菌( HELICOBACTER PYLORI )......................1 1-1-1幽門螺旋桿菌及相關感染疾病..............................1 1-2膽固醇糖苷類( CHOLESTERYL GLUCOSIDES DERIVATIVES,CGDS )..2 1-2-1膽固醇糖苷類的發現與概要...............................2 1-2-2膽固醇醣苷 ( Cholesteryl glucosides ) 之功能........ 3 1-2-3產生膽固醇-α-D-口比喃葡萄醣苷 ( CG ) 之相對基因hp0421.................................................. 4 1-2-4產生膽固醇-6-O-醯基-α-D-口比喃葡醣苷 ( CAG ) 之相對基因hp0499....................................................5 1-3大腸桿菌外膜磷酸脂酶ESCHERICHIA COLI. OUTER MEMBRANE PHOSPHOLIPASE A ( OMPLA ).................................6 1-4 論文研究動機 ..........................................8 2-1幽門螺旋桿菌HP0499重組蛋白建構 ..........................9 2-1-1幽門螺旋桿菌HP0499重組蛋白之基因轉殖................ 9 2-1-2 幽門螺旋桿菌之重組蛋白小量表現測試....................9 2-1-3 幽門螺旋桿菌之重組蛋白大量表現.......................10 2-2 HP0499重組蛋白之純化.................................10 2-2-1 重組蛋白之純化(細胞破碎後之上清液)................. 10 2-2-2 將重組蛋白變性後進行之純化..........................11 2-2-3 利用界面活性劑回溶表現在包涵體的重組蛋白進行之純化....13 2-2-4利用界面活性劑與細胞萃取液作用後之重組蛋白進行純化.....14 2-2-5蛋白質定量..........................................16 2-2-6 銀染法 ( Silver stain )............................16 2-3帶有螢光標定之膽固醇-Α-D-口比喃葡萄醣苷 ( CG ) 製備.....17 2-3-1幽門螺旋桿菌菌株和細菌培養...........................17 2-3-2膽固醇-α-D-口比喃葡萄醣苷 ( CG ) 小量分析............18 2-3-3大量表現帶有螢光標定之膽固醇-α-D-口比喃葡萄醣苷 ( CG ) ........................................................18 2-3-4 帶有螢光標定之膽固醇-α-D-口比喃葡萄醣苷 ( CG ) 之純化 ........................................................19 2-3-5膽固醇-α-D-口比喃葡萄醣苷(CG)定量(高效液相色譜法)..20 2-4 磷酸脂微溶脂形式製備..................................21 2-5 幽門螺旋桿菌HP0499之特性及活性鑑定....................21 2-5-1 HP0499酵素動力學分析..............................24 2-5-2 酵素動力學參數計算..................................25 第三章 實驗結果...........................................26 3-1 幽門螺旋桿菌HP0499重組蛋白之建構與純化 .................26 3-1-1 質體建構............................................26 3-1-2 質體轉殖後小量表現...................................26 3-1-3 幽門螺旋桿菌HP0499大量表現與純化......................27 3-1-4 幽門螺旋桿菌重組蛋白HP0499蛋白變性後之純化............27 3-1-5 利用界面活性劑大量純化MBP-HP0499蛋白.................28 3-1-6 幽門螺旋桿菌HP0499純度及西方墨點法分析................29 3-2帶有螢光標定之膽固醇-Α-D-口比喃葡萄醣苷 ( CG ) 製備......29 3-2-1幽門螺旋桿菌菌種篩選及培養時間........................30 3-3 幽門螺旋桿菌HP0499蛋白之生化特性分析與酵素動力學探討....31 3-3-1 時間-產物量關係探討.................................31 3-3-2 HP0499蛋白最適當反應溫度............................32 3-3-3 HP0499蛋白最適當反應pH值............................32 3-3-4 HP0499蛋白最適當的金屬輔因子........................33 3-3-5 有機溶劑耐受性分析..................................33 3-3-6 受質專一性分析......................................35 3-3-7 酵素動力學分析......................................36 第四章 討論、結論、與未來展望.............................37 第五章 圖表..............................................38 第六章 參考文獻........................................ 66 | |
dc.language.iso | zh-TW | |
dc.title | 幽門螺旋桿菌基因 hp0499 製備與性質探討 | zh_TW |
dc.title | Preparation and characterization of Helicobacter pylori gene hp0499 | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳佩燁,吳世雄 | |
dc.subject.keyword | 幽門螺旋桿菌,細胞毒素相關蛋白A,膽固醇-6-O-醯基-α-D-口比喃葡萄糖?,磷酸脂?A1, | zh_TW |
dc.subject.keyword | Helicobacter pylori,Cag A,CAG,phospholipaseA1, | en |
dc.relation.page | 72 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-19 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 3.11 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。